Abstract: The invention relates to recombinant viral vectors for the insertion and expression of foreign genes for use in safe immunizations to protect against a variety of pathogens. The invention also relates to multivalent compositions or vaccine comprising one or more recombinant viral vectors for protection against a variety of pathogens. The present invention relates to methods of making an using said recombinant viral vectors.

Abstract: The invention relates to recombinant viral vectors for the insertion and expression of foreign genes for use in safe immunizations to protect against a variety of pathogens. The invention also relates to multivalent compositions or vaccine comprising one or more recombinant viral vectors for protection against a variety of pathogens. The present invention relates to methods of making an using said recombinant viral vectors.

Abstract: The invention relates to recombinant viral vectors for the insertion and expression of foreign genes for use in safe immunizations to protect against a variety of pathogens. The invention also relates to multivalent compositions or vaccine comprising one or more recombinant viral vectors for protection against a variety of pathogens. The present invention relates to methods of making an using said recombinant viral vectors.

Abstract: The invention relates to recombinant viral vectors for the insertion and expression of foreign genes for use in safe immunizations to protect against a variety of pathogens. The invention also relates to multivalent compositions or vaccine comprising one or more recombinant viral vectors for protection against a variety of pathogens. The present invention relates to methods of making an using said recombinant viral vectors.

Abstract: A negative bit line write assist system includes an array voltage supply and a static random access memory (SRAM) cell that is coupled to the array voltage supply and controlled by bit lines during a write operation. Additionally, the negative bit line write assist system includes a bit line voltage unit that is coupled to the SRAM cell, wherein a distributed capacitance is controlled by a write assist command to provide generation of a negative bit line voltage during the write operation. A negative bit line write assist method is also provided.

Abstract: A hybrid write-assist memory system includes an array voltage supply and a static random access memory (SRAM) cell that is controlled by bit lines and a word line and employs a separable cell supply voltage coupled to the array voltage supply. Additionally, the hybrid write-assist memory system includes a supply voltage droop unit that is coupled to the SRAM cell and provides a voltage reduction of the separable cell supply voltage during a write operation. Also, the hybrid write-assist memory system includes a negative bit line unit that is coupled to the supply voltage droop unit and provides a negative bit line voltage concurrently with the voltage reduction of the separable cell supply voltage during the write operation. A method of operating a hybrid write-assist memory system is also provided.

Abstract: A negative bit line write assist system includes an array voltage supply and a static random access memory (SRAM) cell that is coupled to the array voltage supply and controlled by bit lines during a write operation. Additionally, the negative bit line write assist system includes a bit line voltage unit that is coupled to the SRAM cell, wherein a distributed capacitance is controlled by a write assist command to provide generation of a negative bit line voltage during the write operation. A negative bit line write assist method is also provided.

Abstract: A hybrid write-assist memory system includes an array voltage supply and a static random access memory (SRAM) cell that is controlled by bit lines and a word line and employs a separable cell supply voltage coupled to the array voltage supply. Additionally, the hybrid write-assist memory system includes a supply voltage droop unit that is coupled to the SRAM cell and provides a voltage reduction of the separable cell supply voltage during a write operation. Also, the hybrid write-assist memory system includes a negative bit line unit that is coupled to the supply voltage droop unit and provides a negative bit line voltage concurrently with the voltage reduction of the separable cell supply voltage during the write operation. A method of operating a hybrid write-assist memory system is also provided.

Abstract: The present invention relates to a vaccine composition against feline calicivirus (CFV) infection. The composition comprises a capsid protein of Feline calicivirus-49 (CFV-49), a pharmaceutical accepted carrier and optionally an adjuvant. The present invention further relates to a feline vaccine composition further comprises other live, attenuated or inactivated CVF component in addition to the capsid protein of FCV-49. The present invention also relates to a method for making or using the vaccine compositions.

Abstract: The present invention relates to a vaccine for immunizing a cat against feline viruses. The present invention also relates to a nucleic acid clone that encodes the capsid protein of the isolated feline calicivirus. The present invention further relates to a live or killed vaccine comprising the isolated feline calicivirus, a subunit vaccine comprising the capsid protein of the isolated feline calicivirus, a nucleic acid vaccine comprising a nucleic acid clone of the isolated feline calicivirus, and a recombinant virus vector vaccine comprising nucleic acid encoding the capsid protein of the isolated feline calicivirus. The present invention also relates to a method for identifying a feline calicivirus useful for producing a vaccine composition and for assays for diagnosing cats infected with feline calicivirus. Also disclosed is a method of immunizing animals, especially cats, against disease, in particular against feline calicivirus (FCV).

Abstract: The present invention relates to a vaccine for immunizing a cat against feline viruses. The present invention also relates to a nucleic acid clone that encodes the capsid protein of the isolated feline calicivirus. The present invention further relates to a live or killed vaccine comprising the isolated feline calicivirus, a subunit vaccine comprising the capsid protein of the isolated feline calicivirus, a nucleic acid vaccine comprising a nucleic acid clone of the isolated feline calicivirus, and a recombinant virus vector vaccine comprising nucleic acid encoding the capsid protein of the isolated feline calicivirus. The present invention also relates to a method for identifying a feline calicivirus useful for producing a vaccine composition and for assays for diagnosing cats infected with feline calicivirus. Also disclosed is a method of immunizing animals, especially cats, against disease, in particular against feline calicivirus (FCV).

Abstract: The present invention relates to a vaccine for immunizing a cat against feline viruses. The present invention also relates to a nucleic acid clone that encodes the capsid protein of the isolated feline calicivirus. The present invention further relates to a live or killed vaccine comprising the isolated feline calicivirus, a subunit vaccine comprising the capsid protein of the isolated feline calicivirus, a nucleic acid vaccine comprising a nucleic acid clone of the isolated feline calicivirus, and a recombinant virus vector vaccine comprising nucleic acid encoding the capsid protein of the isolated feline calicivirus. The present invention also relates to a method for identifying a feline calicivirus useful for producing a vaccine composition and for assays for diagnosing cats infected with feline calicivirus. Also disclosed is a method of immunizing animals, especially cats, against disease, in particular against feline calicivirus (FCV).

Abstract: The present invention relates to polynucleotides associated with apoptosis-related disorders. The present invention also relates to canine and feline TRAIL genes, novel genes associated with apoptosis-related disorders, such as cancer. The invention encompasses TRAIL nucleic acids, recombinant DNA molecules, cloned genes or degenerate variants thereof, TRAIL gene products and antibodies directed against such gene products, cloning vectors containing mammalian TRAIL gene molecules, and hosts that have been genetically engineered to express such molecules. The invention further relates to methods for the identification of compounds that modulate the expression of TRAIL genes and gene products and to the use of such compounds as therapeutic agents in the treatment of apoptosis-related disorders, e.g., cancer. The invention also relates to methods for the diagnostic evaluation, genetic testing and prognosis of apoptosis-related disorders, e.g.

Abstract: The present invention relates to mammalian cell lines which efficiently support the growth and productive infection of Marek's Disease Virus at high titers. The present invention also relates to mammalian cell lines which have been engineered to support the growth and productive infection of recombinant Marek's Disease Virus at high titers. The present invention relates a process for the preparation of Marek's Disease Virus in quantities suitable for vaccine purposes.

Abstract: An amplifier distortion reduction system obtains a distortion signal from the amplifier output and feeds the distortion signal back to the input side of the amplifier to cancel with the distortion produced at the amplifier output. For example, a signal to be amplified by an amplifier is received on a main signal path. The amplifier produces an amplified output with a non-distortion spectrum and a distortion spectrum. A sample of the amplified output is produced from the main signal path and placed on a feedback path. On the feedback path, the distortion spectrum is obtained from the sample amplified output. The distortion spectrum is phase and/or amplitude adjusted to produce the distortion signal. The distortion signal is placed onto the main signal path at the input side of the amplifier with the signal to be amplified to destructively combine with the distortion produced from the amplifier in amplifying the signal to be amplified.

Abstract: The present invention relates to avian cell lines which efficiently support the growth and productive infection of Marek's Disease Virus at high titers. The present invention also relates to avian cell lines which have been engineered to support the growth and productive infection of recombinant Marek's Disease Virus at high titers. The present invention relates a process for the preparation of Marek's Disease Virus in quantities suitable for vaccine purposes.

Abstract: A method of preventing tumor cell metastasis by inhibiting the binding of hepatocyte growth factor/scatter factor ("HGF/SF") with met proto-oncogene protein is described. A method of producing HGF/SF and a cell line for the production of HGF/SF are also described. The met proto-oncogene tyrosine kinase receptor (Met) and its ligand, hepatocyte growth factor/scatter factor (HGF/SF), ordinarily constitute a paracrine signalling system in which cells of mesenchymal origin produce the ligand, which binds to the receptor that is predominantly expressed in cells of epithelial origin. The method of the present invention disrupts the Met-HGF/SF autocrine signaling that contributes to the tumorigenic process in tumors of mesenchymal origin, such as sarcomas.